Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4414/smw.2004.10532 http://scihub22266oqcxt.onion/10.4414/smw.2004.10532 15616901!ä!15616901 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Swiss+Med+Wkly 2004 ; 134 (47-48): 685-94 Nephropedia Template TP {{tp|p=15616901|t=2004. Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy |pdf=|usr=}}{{15616901}} gab.com Text Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy JO: Swiss Med Wkly http://www.kidney.de/pget.php?&tw=1&pmid=15616901 #FOAvip More than 70 drugs present on the Swiss market can cause drug-induced long QT syndrome (LQTS), which is associated with torsades de pointes (TdP) arrhythmias, potentially leading to sudden cardiac death. Basic and clinical investigations performed during the last decade have helped a better understanding of the mechanisms and risk factors of this serious public health problem. In their vast majority, QT interval prolonging drugs block the human ERG (hERG) channel involved in the repolarisation phase of the cardiac action potential, and thus lengthen the QT interval. Beside the well-known QT interval prolonging action of class IA, IC and III anti-arrhythmic drugs, many antibiotics, neurotropic, antifungal, and antimalarial drugs are also able to cause drug-induced LQTS. Reviewing the literature indicates that the risk of QT interval prolongation and TdP is increased in females, in patients with organic heart diseases and hypokalaemia. Furthermore in a few cases, genetic factors have also been reported. However thus far, no genetic test is available to detect at-risk patients, and in consequence, drug prescribers are still relying only on the clinical history and findings to perform an evaluation of the risk. Treatment of drug-induced LQTS and TdP includes identifying and withdrawing the culprit drug(s), infusing magnesium and, in resistant cases acceleration of the heart rate. In this review article we provide a list of QT interval prolonging drugs adapted to the pharmaceuticals found on the Swiss market that can be used as a check-list for drug prescribers and at-risk patients. Twit Text FOAVip Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy ????Swiss Med Wkly http://www.kidney.de/pget.php?&tw=1&pmid=15616901 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=15616901 #FOAvip English Wikipedia <ref>{{Cite pmid|15616901}}</ref> Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy #MMPMID15616901 Abriel H; Schlapfer J; Keller DI; Gavillet B; Buclin T; Biollaz J; Stoller R; Kappenberger L Swiss Med Wkly 2004[Nov]; 134 (47-48): 685-94 PMID15616901show ga More than 70 drugs present on the Swiss market can cause drug-induced long QT syndrome (LQTS), which is associated with torsades de pointes (TdP) arrhythmias, potentially leading to sudden cardiac death. Basic and clinical investigations performed during the last decade have helped a better understanding of the mechanisms and risk factors of this serious public health problem. In their vast majority, QT interval prolonging drugs block the human ERG (hERG) channel involved in the repolarisation phase of the cardiac action potential, and thus lengthen the QT interval. Beside the well-known QT interval prolonging action of class IA, IC and III anti-arrhythmic drugs, many antibiotics, neurotropic, antifungal, and antimalarial drugs are also able to cause drug-induced LQTS. Reviewing the literature indicates that the risk of QT interval prolongation and TdP is increased in females, in patients with organic heart diseases and hypokalaemia. Furthermore in a few cases, genetic factors have also been reported. However thus far, no genetic test is available to detect at-risk patients, and in consequence, drug prescribers are still relying only on the clinical history and findings to perform an evaluation of the risk. Treatment of drug-induced LQTS and TdP includes identifying and withdrawing the culprit drug(s), infusing magnesium and, in resistant cases acceleration of the heart rate. In this review article we provide a list of QT interval prolonging drugs adapted to the pharmaceuticals found on the Swiss market that can be used as a check-list for drug prescribers and at-risk patients. |*Iatrogenic Disease[MESH] |Anti-Arrhythmia Agents/*pharmacology[MESH] |Death, Sudden, Cardiac/etiology[MESH] |Female[MESH] |Humans[MESH] |Long QT Syndrome/*chemically induced[MESH] |Male[MESH] |Pharmacogenetics[MESH] |Potassium Channels, Voltage-Gated/drug effects[MESH] |Safety[MESH]Molecular and clinical determinants of drug-induced long QT syndrome: (epmc).pdf DeepDyve Pubget Overpricing